Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease.
O'Neill
Michael J
MJ
Eli Lilly and Co. Ltd., Lilly Research Centre, Erl Wood Manor, Windlesham Surrey GU20 6PH, United Kingdom.
Messenger
Marcus J
MJ
Lakics
Viktor
V
Murray
Tracey K
TK
Karran
Eric H
EH
Szekeres
Philip G
PG
Nisenbaum
Eric S
ES
Merchant
Kalpana M
KM
D000818:Animals; D016503:Drug Delivery Systems; D006801:Humans; D009414:Nerve Growth Factors / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D010300:Parkinson Disease / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D018091:Receptors, AMPA / Q000819:agonists; D033581:Stem Cell Transplantation
D009414:Nerve Growth Factors; D018696:Neuroprotective Agents; D018091:Receptors, AMPA